A New Score to Predict the Resectability ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Permalink :
Title :
A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score
Author(s) :
Maulat, Charlotte [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Canivet, Cindy [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Touraine, Célia [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Gourgou, Sophie [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Napoleon, Bertrand [Auteur]
Palazzo, Laurent [Auteur]
Flori, Nicolas [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Piessen, Guillaume [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Guibert, Pierre [Auteur]
Centre Léon Bérard [Lyon]
Truant, Stéphanie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Assenat, Eric [Auteur]
Institut de Génétique Moléculaire de Montpellier [IGMM]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Buscail, Louis [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Bournet, Barbara [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Muscari, Fabrice [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Canivet, Cindy [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Touraine, Célia [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Gourgou, Sophie [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Napoleon, Bertrand [Auteur]
Palazzo, Laurent [Auteur]
Flori, Nicolas [Auteur]
Institut régional de Cancérologie de Montpellier [ICM]
Piessen, Guillaume [Auteur]

Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Guibert, Pierre [Auteur]
Centre Léon Bérard [Lyon]
Truant, Stéphanie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Assenat, Eric [Auteur]
Institut de Génétique Moléculaire de Montpellier [IGMM]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Buscail, Louis [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Bournet, Barbara [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Muscari, Fabrice [Auteur]
Centre de Recherches en Cancérologie de Toulouse [CRCT]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Journal title :
Cancers
Pages :
783
Publisher :
MDPI
Publication date :
2020
ISSN :
2072-6694
English keyword(s) :
BACAP cohort
Pancreatic ductal adenocarcinoma
locally advanced
metastasis
pancreatic cancer
predictive factors
resectability
score
pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma
locally advanced
metastasis
pancreatic cancer
predictive factors
resectability
score
pancreatic ductal adenocarcinoma
HAL domain(s) :
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hépatologie et Gastroentérologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hépatologie et Gastroentérologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie
English abstract : [en]
Surgery remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Therefore, a predictive score for resectability on diagnosis is needed. A total of 814 patients were included between 2014 and 2017 ...
Show more >Surgery remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Therefore, a predictive score for resectability on diagnosis is needed. A total of 814 patients were included between 2014 and 2017 from 15 centers included in the BACAP (the national Anatomo-Clinical Database on Pancreatic Adenocarcinoma) prospective cohort. Three groups were defined: resectable (Res), locally advanced (LA), and metastatic (Met). Variables were analyzed and a predictive score was devised. Of the 814 patients included, 703 could be evaluated: 164 Res, 266 LA, and 273 Met. The median ages of the patients were 69, 71, and 69, respectively. The median survival times were 21, 15, and nine months, respectively. Six criteria were significantly associated with a lower probability of resectability in multivariate analysis: venous/arterial thrombosis (p = 0.017), performance status 1 (p = 0.032) or ≥ 2 (p = 0.010), pain (p = 0.003), weight loss ≥ 8% (p = 0.019), topography of the tumor (body/tail) (p = 0.005), and maximal tumor size 20–33 mm (p < 0.013) or >33 mm (p < 0.001). The BACAP score was devised using these criteria with an accuracy of 81.17% and an area under the receive operating characteristic (ROC) curve of 0.82 (95% confidence interval (CI): 0.78; 0.86). The presence of pejorative criteria or a BACAP score < 50% indicates that further investigations and even neoadjuvant treatment might be warranted. Trial registration: NCT02818829.Show less >
Show more >Surgery remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Therefore, a predictive score for resectability on diagnosis is needed. A total of 814 patients were included between 2014 and 2017 from 15 centers included in the BACAP (the national Anatomo-Clinical Database on Pancreatic Adenocarcinoma) prospective cohort. Three groups were defined: resectable (Res), locally advanced (LA), and metastatic (Met). Variables were analyzed and a predictive score was devised. Of the 814 patients included, 703 could be evaluated: 164 Res, 266 LA, and 273 Met. The median ages of the patients were 69, 71, and 69, respectively. The median survival times were 21, 15, and nine months, respectively. Six criteria were significantly associated with a lower probability of resectability in multivariate analysis: venous/arterial thrombosis (p = 0.017), performance status 1 (p = 0.032) or ≥ 2 (p = 0.010), pain (p = 0.003), weight loss ≥ 8% (p = 0.019), topography of the tumor (body/tail) (p = 0.005), and maximal tumor size 20–33 mm (p < 0.013) or >33 mm (p < 0.001). The BACAP score was devised using these criteria with an accuracy of 81.17% and an area under the receive operating characteristic (ROC) curve of 0.82 (95% confidence interval (CI): 0.78; 0.86). The presence of pejorative criteria or a BACAP score < 50% indicates that further investigations and even neoadjuvant treatment might be warranted. Trial registration: NCT02818829.Show less >
Language :
Anglais
Popular science :
Non
Source :
Submission date :
2024-02-17T04:23:32Z
Files
- document
- Open access
- Access the document
- cancers-12-00783-v2.pdf
- Open access
- Access the document